The purpose of this clinical trial is to assess the efficacy and safety of cell therapy with modified leukocyte cells from the participant himself/herself versus placebo in participants who develop Acute Kidney Injury (AKI) within the first 48 hours after cardiac surgery.
The main questions it aims to answer are:
* Does cell therapy reduce the recovery time of kidney function?
* What medical problems do participants have when receiving cell therapy?
Researchers will compare cell therapy with a placebo (a look-alike substance that contains no drug) to see if cell therapy works to treat AKI. The safety of cell therapy with leukocyte cells will also be studied.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-26; most recent amendment 2026-05-07.
Status change: Not Yet Recruiting → Recruiting2026-05-07